Recent polling shows oncologists changing inclination in treatment for mHSPC based on tolerability profiles.

The median BMI of the cohort was 26.7 kg/m 2 (range, 17.9–55.2). Patients were classified into 3 main weight categories based ...

The division of myelodysplastic syndromes (MDS) into low-risk and high-risk categories guides prognosis and treatment, with patients who have lower-risk disease typically receivin ...

Findings from a prospective phase 2 clinical trial show that isatuximab (Sarclisa), an anti-CD38 monoclonal antibody, is an effective and well-tolerated treatment for patients with relapsed and/or ...

RP1 and nivolumab combination achieved a 32.9% objective response rate and 15.0% complete response rate in advanced melanoma ...

Visugromab combined with nivolumab showed a median duration of response exceeding two years in refractory NSCLC, UC, and HCC patients. GDF-15 is a therapeutic target and immune escape mechanism, ...

Topline results from the phase 3 HERIZON-GEA-01 trial show that the HER2-targeted bispecific antibody zanidatamab-hrii ...

Dr. Christian S. Hinrichs discusses the future of specialized cell therapies, predicting broader access for community clinics similar to CAR T cell treatments.

GLP-1 RAs are associated with a 62% reduction in 5-year mortality in colon cancer patients, especially those with high obesity. The study's findings remained significant after adjusting for ...

A significant communication gap exists between NMIBC patients and providers, with only 18% having regular discussions about ...

Systemic immunotherapy is emerging as a bladder-sparing option for NMIBC, especially for patients unresponsive to BCG therapy ...

The FDA approved enfortumab vedotin and pembrolizumab for MIBC, following a priority review of their sBLA for neoadjuvant and ...